Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07137390) titled 'Phase Ib/II Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer' on Aug. 15.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: M.D. Anderson Cancer Center
Condition:
Colorectal Cancer
Intervention:
Drug: Regorafenib
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: February 28, 2026
Target Sample Size: 30
Countries of Recruitment:
United States
To know m...